Placenta
Volume 30, Issue 12 , Pages 1065-1070, December 2009

Therapeutic Effects of Anticoagulant Agents on Preeclampsia in a Murine Model Induced by Phosphatidylserine/Phosphatidylcholine Microvesicles

  • Y. Zhang

      Affiliations

    • Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, China
  • ,
  • Z. Hua

      Affiliations

    • State Key Laboratory of Pharmaceutical Biotechnology, College of Life Sciences, Nanjing University, China
  • ,
  • K. Zhang

      Affiliations

    • Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, China
  • ,
  • K. Meng

      Affiliations

    • Department of Pathology, Nanjing Drum Tower Hospital, Nanjing University Medical School, China
  • ,
  • Y. Hu

      Affiliations

    • Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, China
    • Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, 321 Zhongshan Road, Nanjing 210008, China. Tel.: +86 25 8332 1980.

Accepted 17 September 2009. published online 19 October 2009.

Abstract 

Preeclampsia (PE) is a placenta-mediated pregnancy complication that results in high maternal and neonatal mortality and morbidity worldwide. Currently, there is no satisfactory pharmacotherapeutic treatment to stop the PE progression. In this study, we investigated the therapeutic effects of anticoagulant agents, including annexin V, heparin, and a fusion protein of annexin V and hirudin (AND), in a murine PE model induced by intravenous injection of phosphatidylserine/phosphatidylcholine (PS/PC) microvesicles. Compared with the control pregnant animals, the pregnant mice injected with PS/PC presented PE-like symptoms, including elevated systolic blood pressure, proteinuria, and reduction of antithrombin III and blood platelets. However, the PE-like symptoms were significantly alleviated after the PS/PC-injected mice were treated with annexin V, AND, or heparin. Furthermore, fibrin deposition in the placentas in the anticoagulant treated mice was remarkably improved, compared with that in the mice injected with PS/PC alone. The data demonstrate that anticoagulants are effective to prevent the occurrence of PE in the murine model and also suggest that hypercoagulation in the placenta is a contributing factor in the pathogenesis of PE.

Keywords: Preeclampsia, Abnormal coagulation, Anticoagulants, Therapeutic effect, Murine model

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0143-4004(09)00300-2

doi:10.1016/j.placenta.2009.09.004

Placenta
Volume 30, Issue 12 , Pages 1065-1070, December 2009